Olema Pharmaceuticals (OLMA) sees 9.99% stake from Bain Capital

Rhea-AI Filing Summary

Bain Capital Life Sciences Opportunities IV, L.P. has reported a passive ownership stake in Olema Pharmaceuticals, Inc. common stock on a Schedule 13G/A. As of December 31, 2025, it is deemed to beneficially own 8,508,641 shares, representing 9.99% of the outstanding common stock.

The position consists of 1,989,775 common shares and pre-funded warrants initially exercisable for up to 8,013,216 additional shares, but a 9.99% “Beneficial Ownership Blocker” caps how many warrant shares are counted for regulatory purposes. The filing states the securities were not acquired to change or influence control of Olema.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

OLEMA PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

68062P106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68062P106

1

Names of Reporting Persons

Bain Capital Life Sciences Opportunities IV, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,508,641.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,508,641.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,508,641.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OLEMA PHARMACEUTICALS, INC.
(b)	Address of issuer's principal executive offices: 780 Brannan Street, San Francisco, California 94103
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities IV, L.P., a Delaware limited partnership (the "Reporting Person"). Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences IV General Partner, LLC, a Delaware limited liability company ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P., a Delaware limited partnership ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund IV GP and BCLS Fund IV, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.
(c)	Citizenship: Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 68062P106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of December 31, 2025, the Reporting Person held 1,989,775 shares of Common Stock and pre-funded warrants to purchase up to 8,013,216 shares of Common Stock. The Reporting Person is prohibited from exercising the pre-funded warrants if, as a result of such exercise, the Reporting Person would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Blocker"). Accordingly, pursuant to Rule 13d-3 of the Act, the Reporting Person may be deemed to beneficially own 9.99% of the outstanding shares of Common Stock, representing 8,508,641 shares of Common Stock as of December 31, 2025. The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on (i) 78,652,730 shares of Common Stock outstanding as of November 20, 2025, as reported by the Issuer in its prospectus supplement filed with the Securities and Exchange Commission on November 19, 2025 and (ii) 6,518,866 shares of Common Stock issuable upon the partial exercise of the pre-funded warrants held by the Reporting Person, which reflects the Beneficial Ownership Blocker.
(b)	Percent of class: See Item 4(a) hereof.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: See Item 4(a) hereof.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: See Item 4(a) hereof.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bain Capital Life Sciences Opportunities IV, L.P.

Signature:	/s/ Andrew Hack
Name/Title:	Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
Date:	02/17/2026

FAQ

What stake in Olema Pharmaceuticals (OLMA) does Bain Capital report?

Bain Capital Life Sciences Opportunities IV, L.P. reports a 9.99% beneficial ownership stake in Olema Pharmaceuticals common stock, equal to 8,508,641 shares as of December 31, 2025. This combines owned shares and warrant-linked shares within the regulatory ownership cap.

How many Olema (OLMA) shares and warrants does Bain Capital hold?

Bain Capital holds 1,989,775 Olema common shares and pre-funded warrants to purchase up to 8,013,216 additional shares. Due to the 9.99% ownership cap, only part of the warrant shares are counted toward the 8,508,641 shares deemed beneficially owned.

What is the 9.99% Beneficial Ownership Blocker in the Olema (OLMA) filing?

The 9.99% Beneficial Ownership Blocker prevents Bain Capital from exercising its pre-funded warrants if doing so would push its beneficial ownership above 9.99% of Olema’s outstanding common stock. This limiter shapes how many warrant shares are included in the reported 8,508,641 shares.

On what share count is Bain Capital’s 9.99% Olema (OLMA) stake based?

The 9.99% stake is calculated using 78,652,730 Olema common shares outstanding as of November 20, 2025, plus 6,518,866 shares issuable upon partial exercise of Bain Capital’s pre-funded warrants. This combination yields the 8,508,641 shares deemed beneficially owned.

Is Bain Capital seeking control of Olema Pharmaceuticals (OLMA)?

The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of Olema. It characterizes Bain Capital’s position as passive, consistent with a Schedule 13G/A rather than an activist Schedule 13D filing.

Who signed the Bain Capital Schedule 13G/A for Olema (OLMA)?

The Schedule 13G/A was signed by Andrew Hack, identified as a Partner of Bain Capital Life Sciences Investors, LLC. His signature certifies that, to his knowledge and belief, the information in the statement is true, complete, and correct as of the filing date.